Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines

Tools
- Tools
+ Tools

Cheeseman, M. D., Faisal, A., Rayter, S., Barbeau, O. R., Kalusa, A., Westlake, M., Burke, R., Swan, M., van Montfort, R., Linardopoulos, S., Jones, K. (2014) Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 24 (15). pp. 3469-3474. ISSN 0960-894X

Full text not available from this repository.

Abstract

The metal-dependent phosphatase PPM1D (WIP1) is an important oncogene in cancer, with over-expression of the protein being associated with significantly worse clinical outcomes. In this communication we describe the discovery and optimization of novel 2,4-bisarylthiazoles that phenocopy the knockdown of PPM1D, without inhibiting its phosphatase activity. These compounds cause growth inhibition at nanomolar concentrations, induce apoptosis, activate p53 and display impressive cell-line selectivity. The results demonstrate the potential for targeting phenotypes in drug discovery when tackling challenging targets or unknown mechanisms. (C) 2014 Published by Elsevier Ltd.

Item Type: Article
Authors (ICR Faculty only): Jones, Keith and Linardopoulos, Spiros and Van Montfort, Rob
All Authors: Cheeseman, M. D., Faisal, A., Rayter, S., Barbeau, O. R., Kalusa, A., Westlake, M., Burke, R., Swan, M., van Montfort, R., Linardopoulos, S., Jones, K.
Additional Information: ISI Document Delivery No.: AL6FT Times Cited: 0 Cited Reference Count: 22 Cheeseman, Matthew D. Faisal, Amir Rayter, Sydonia Barbeau, Olivier R. Kalusa, Andrew Westlake, Maura Burke, Rosemary Swan, Michael van Montfort, Rob Linardopoulos, Spiros Jones, Keith Cancer Research UK [C309/A8274, C309/A11566]; Institute of Cancer Research This work was supported by Cancer Research UK grant numbers C309/A8274 and C309/A11566, and by The Institute of Cancer Research. 0 PERGAMON-ELSEVIER SCIENCE LTD OXFORD BIOORG MED CHEM LETT
Uncontrolled Keywords: PPM1D Phenotype Apoptosis p53 2,4-Bisarylthiazole BREAST-CANCER WIP1 INHIBITOR ASSAY AMPLIFICATION PHOSPHATASES DISCOVERY P53
Research teams: ICR divisions > Breast Cancer Research > Drug Target Discovery
ICR divisions > Cancer Therapeutics > Drug Target Discovery

ICR divisions > Cancer Therapeutics > Hit Discovery & Structural Design
ICR divisions > Structural Biology > Hit Discovery & Structural Design

ICR divisions > Breast Cancer Research > Target Discovery & Apoptosis
ICR divisions > Cancer Therapeutics > Target Discovery & Apoptosis

ICR divisions > Cancer Therapeutics > Medicinal Chemistry 3
ICR divisions > Cancer Therapeutics > Structure-Based Drug Design
ICR divisions > Structural Biology > Structure-Based Drug Design
Depositing User: Users 11 not found.
Date Deposited: 04 Sep 2014 11:52
Last Modified: 04 Sep 2014 11:52
URI: http://publications.icr.ac.uk/id/eprint/13440

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust